title: Safety creatinine clearance level for platinum chemotherapy in lung cancer patients.
abstract: The present study was carried out to evaluate whether measured-creatinine clearance (measured-CrCl) and Cockcroft and Gault-CrCl (CG-CrCl) are capable of appropriately detecting a decline in renal function in lung cancer patients, including elderly patients, and to clarify a CrCl level with which to discriminate between patients with or without renal impairment. The measured-CrCl prior and subsequent to platinum-based chemotherapy of lung cancer patients was retrospectively analyzed. Measured-CrCl and CG-CrCl were evaluated prior and subsequent to platinum-based chemotherapy for lung cancer. Measured-CrCl and CG-CrCl in 59 lung cancer patients including 25 patients aged ≥65 years were retrospectively analyzed. In patients treated with carboplatin-based chemotherapy, measured-CrCl was indicative of a decline in renal function, whereas CG-CrCl was not. The optimal measured-CrCl level was <60 ml/min post-pretreatment and >90 ml/min at pre-treatment. In cases with pre-treatment measured-CrCl levels of >90 ml/min, favorable renal function is necessary in order to carry out platinum-based chemotherapy in lung cancer patients, including the elderly.
authors: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki.
authors: Gen
authors: G
authors: Ohara
authors: Kunihiko
authors: K
authors: Miyazaki
authors: Koichi
authors: K
authors: Kurishima
authors: Katsunori
authors: K
authors: Kagohashi
authors: Hiroichi
authors: H
authors: Ishikawa
authors: Hiroaki
authors: H
authors: Satoh
authors: Nobuyuki
authors: N
authors: Hizawa